Saving costs in cancer patient management through molecular imaging.
作者信息
von Gall Carl, Maniawski Piotr, Verzijlbergen Fred, Carrio Ignasi, Beyer Thomas, Kalemis Antonis
机构信息
Siemens Healthineers, Molecular Imaging, Knoxville, TN, USA.
Philips Healthcare, Advanced Molecular Imaging, Cleveland, OH, USA.
出版信息
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2153-2157. doi: 10.1007/s00259-017-3804-3. Epub 2017 Aug 14.
Abstract
摘要
相似文献
1
Saving costs in cancer patient management through molecular imaging.
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2153-2157. doi: 10.1007/s00259-017-3804-3. Epub 2017 Aug 14.
2
PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1749-52. doi: 10.1007/s00259-016-3414-5. Epub 2016 May 13.
3
Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial.
J Oncol Pract. 2016 Jul;12(7):e765-74. doi: 10.1200/JOP.2016.011676. Epub 2016 Jun 21.
4
How to scan who: the delicate balance between selecting the patient and selecting the imaging protocol.
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):5-7. doi: 10.1007/s00259-016-3511-5.
5
Segmental F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy.
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):1-4. doi: 10.1007/s00259-016-3532-0.
6
[Not Available].
Rofo. 2016 Sep;188(9):885. doi: 10.1055/s-0042-115358. Epub 2016 Aug 31.
7
[Not Available].
Rofo. 2021 Jun;193(6):733-735. doi: 10.1055/a-1459-0421. Epub 2021 May 20.
8
Evidence-based indications for the use of PET-CT in the United Kingdom 2016.
Clin Radiol. 2016 Jul;71(7):e171-88. doi: 10.1016/j.crad.2016.05.001. Epub 2016 May 17.
9
Long waiting times for test results for NHS patients.
Lancet Oncol. 2016 Jul;17(7):e274. doi: 10.1016/S1470-2045(16)30209-1. Epub 2016 Jun 3.
10
Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using F-FDG-PET-CT and/or diffusion-weighted MRI.
BMC Cancer. 2017 Apr 11;17(1):256. doi: 10.1186/s12885-017-3254-0.
引用本文的文献
1
Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care.
Pharm Pat Anal. 2024;13(4-6):149-160. doi: 10.1080/20468954.2025.2500811. Epub 2025 May 6.
本文引用的文献
1
Bayesian randomized clinical trials: From fixed to adaptive design.
Contemp Clin Trials. 2017 Aug;59:77-86. doi: 10.1016/j.cct.2017.04.010. Epub 2017 Apr 26.
2
Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
Oncology. 2017;92(4):229-242. doi: 10.1159/000452419. Epub 2017 Feb 15.
3
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.
4
PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer.
N Engl J Med. 2016 Apr 14;374(15):1444-54. doi: 10.1056/NEJMoa1514493. Epub 2016 Mar 23.
5
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Theranostics. 2015 Oct 18;5(12):1388-401. doi: 10.7150/thno.13348. eCollection 2015.
6
Cost-effectiveness of PET and PET/computed tomography: a systematic review.
PET Clin. 2015 Jan;10(1):105-24. doi: 10.1016/j.cpet.2014.09.008. Epub 2014 Oct 14.
7
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
8
Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011.
J Nucl Med. 2014 Aug;55(8):1308-10. doi: 10.2967/jnumed.114.138057. Epub 2014 May 29.
9
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28.
10
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.
Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S11-7. doi: 10.1007/s00259-013-2373-3. Epub 2013 Apr 17.
Zotero 插件